The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
 
Phioanh Leia Nghiemphu
Research Funding - Genentech/Roche; Novartis
 
Hye Hyun Bahng
No Relationships to Disclose
 
Albert Lai
Consulting or Advisory Role - Abbvie; Genentech/Roche; Novocure
Research Funding - Genentech/Roche
 
Nadia Faiq
No Relationships to Disclose
 
William H. Yong
Employment - Yong at heart total wellness (I)
Stock and Other Ownership Interests - Yong at heart total wellness (I)
Research Funding - Amgen (Inst)
 
Richard M. Green
No Relationships to Disclose
 
Jonathan Polikoff
Travel, Accommodations, Expenses - Genentech
 
Cynthia Elizabeth Spier
No Relationships to Disclose
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Novocure; Regeneron
Speakers' Bureau - Prime Oncology
 
Andrew B. Lassman
Honoraria - Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; BioClinica; Cortice Biosciences; Genentech/Roche; Novartis; Novocure; Oxigene; Regeneron; SapVax; VBI Vaccines
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); e-Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Novocure (Inst); Novocure (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Stemline Therapeutics (Inst); Tocagen (Inst); VBL Therapeutics (Inst)
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust